ASCENT-03: Data for Frontline Sacituzumab Govitecan in IO-Ineligible TNBC

The ASCENT-03 trial explores sacituzumab govitecan as a frontline option for patients with advanced TNBC who are not eligible for immune checkpoint inhibitors. Panelists review how this TROP-2–directed ADC demonstrated meaningful clinical activity and durable responses in this challenging subgroup. Compared with traditional chemotherapy, sacituzumab govitecan provided higher response rates and improved progression-free survival, offering a potential new standard for IO-ineligible patients. The panel emphasizes the importance of tailoring treatment to patient-specific factors such as PD-L1 status, prior therapies, and comorbidities. They also note that ADCs like sacituzumab may help bridge the gap in efficacy between IO-eligible and IO-ineligible populations. Ongoing studies will clarify its role in combination strategies and earlier treatment lines.